Appointment of Chief Financial Officer

hVIVO PLC

12 October 2026

 

hVIVO plc

(“hVIVO”, the “Company" or the “Group”)

Appointment of Chief Financial Officer

Angela Hildreth appointed CFO, bringing listed healthcare experience to support growth

London, UK – 12 October 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the appointment of Angela Hildreth as Chief Financial Officer (CFO) and Board Director, with effect from 18 November 2026.

Angela will succeed Richard Cotton, who has served as Interim CFO since October 2026 following Stephen Pinkerton's retirement. Richard will remain in the role until Angela takes up her appointment on 18 November, and after a suitable handover, he will resume his role as Non-Executive Director. As CFO, Angela will lead the Group's finance function and support the continued execution of the Company’s strategy, with a focus on disciplined growth and long-term value creation.

Angela brings over 15 years of strategic and operational financial experience in publicly listed healthcare businesses. She joins hVIVO from Futura Medical plc (AIM: FUM), where she has served as Finance Director and Chief Operating Officer since 2018. She helped guide Futura’s transition from an R&D organisation to international commercialisation, spanning European and US regulatory authorisations, major commercial partnerships and product launches across multiple markets. Angela will continue to serve as a Non-Executive Director of Futura Medical plc for a limited period following the transition of her executive responsibilities.

Prior to Futura Medical, Angela spent seven years as UK Finance Director at Shield Therapeutics plc (AIM: STX), joining the business in 2011 as Financial Controller and becoming UK Finance Director in 2015. She played a central role in its financial and operational build-out through to its AIM listing in 2016. Angela has also served as an Independent Non-Executive Director and Chair of the Audit Committee at AIM-listed Aptamer Group plc.

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: “We are delighted to welcome Angela to hVIVO at an important stage in the Group's development. We have established a differentiated, integrated early clinical development platform, supported by strong commercial momentum and an expanding orderbook, with further opportunity across our four service lines and through our expanded therapeutic offering. Angela’s experience of supporting listed healthcare businesses through operational growth and commercialisation will be highly valuable as we convert these strengths into sustainable, profitable growth and long-term shareholder value.”

Angela Hildreth, incoming Chief Financial Officer of hVIVO, said: “hVIVO occupies a genuinely specialist position in early clinical development, with an integrated platform and a significant opportunity to support clients across more of the drug development pathway. I have been impressed by the strength of the business and look forward to working with Mo, the Board and the wider team to maintain strong financial discipline and support the successful execution of the Company's long-term growth strategy.”

Additional Information on the Board Appointment

The following additional information is provided with regards to the appointment of Angela Hildreth, aged 46, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

Current directorships/partnerships:	Former directorships/partnerships (within the last five years):
Futura Consumer Healthcare Limited	Aptamer Group Plc
Futura Medical Developments Limited	Krumpit Limited
Futura Medical Plc
Quaff Box Limited

Angela Hildreth does not hold any shares or options in the Company.

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

For further information please contact:

hVIVO plc		[phone]
Yamin ‘Mo’ Khan, Chief Executive Officer Richard Cotton, Interim Chief Financial Officer Susan Stuart, Head of IR and Corporate Communications
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				[phone]
Geoff Nash, Callum Davidson, Nigel Birks
Peel Hunt LLP (Joint Broker)		[phone]
James Steel, Dr Christopher Golden
Davy (Joint Broker)		[phone]
Anthony Farrell, Niall Gilchrist
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson			[e-mail]

Notes to Editors

About hVIVO

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

• Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
• Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.
• Human Challenge Trials leverages hVIVO’s state-of-the-art quarantine facility in London – the largest of its kind worldwide – to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.
• Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

 

END